Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous gene-modified gamma delta T cells

A preparation of genetically modified autologous gamma delta T lymphocytes transduced with a lentiviral vector to encode a DNA repair enzyme, with potential immunomodulating and antineoplastic activities. Upon administration, the autologous gene-modified gamma delta T cells secrete interferon-gamma (IFN-g) and exert direct killing of tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. The transduction of gamma delta T cells may confer resistance to alkylating chemotherapeutic agents including temozolomide and allow the use of gamma delta T cells as an adjunct to these agents.
Synonym:autologous DRI-modified gamma delta T cells
autologous drug-resistant gamma-delta T cells
autologous modified gamma delta T cells
Search NCI's Drug Dictionary